Abstract
The objective of the current study is to develop a process for the preparation of Imatinib mesylate of high bulk density from Imatinib free base. Since, crystals of the Imatinib mesylate with various forms were prepared using various reaction conditions and different solvents followed by crystallization. But, most of the process produced Imatinib mesylate with low bulk density. Since in case of Imatinib mesylate dose of 400 mg or 600 mg should be administered once daily, whereas a dose of 800 mg should be administered as 400 mg twice a day, so use of low density Imatinib mesylate for pharmaceutical formulation as solid forms are not favorable. In view of theses facts we developed a process of mesylation in mixture of methanol, ethyl acetate and water which produce Imatinib mesylate with high bulk density which is suitable for the solid formulation. Bulk density of the produced crystals was identified by conventional method.
